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Most children with chromosome 22q11.2 deletion syndrome (22q11DS) have an IQ in the range
that may allow them to be capable of understanding a genetic diagnosis despite mild intellectual
disabilities. However, there are no publications that relate to the disclosure of a 22q11DS
diagnosis to the affected child, or the factors that influence parents’ disclosure to the child. A pilot
study was conducted including eight semi-structured interviews with caregivers of children with
22q11DS, 10 to 17 years of age, to investigate the factors that influence how parents inform their
children of the diagnosis. Six of eight participants had disclosed the diagnosis to the child, and
most of these parents felt they could have benefited from additional advice from professionals to
increase their confidence and success, as well as the child’s comprehension of the information.
Those who had not informed the child were uncertain about the words to use, how to initiate the
conversation, or were concerned about the child’s level of understanding. Our results demonstrate
that genetics professionals should help prepare caregivers for conversations with their children
about the diagnosis of 22q11DS, monitor the understanding of the diagnosis over time, and
provide ongoing support.
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A microdeletion of band q11.2 on chromosome 22 is responsible for over 180 clinical
features and is one of the most common multiple anomaly syndromes found in humans, with
an incidence of about 1 in 2,000 live births (Shprintzen 2008). There are multiple names for
this syndrome, including 22q11.2 deletion syndrome (22q11DS), Velocardiofacial syndrome
(VCFS), and DiGeorge syndrome, and the majority of cases (greater than 90%) are de novo
(reviewed in Shprintzen 2008). Congenital heart defects, palatal anomalies, hypocalcaemia,
immune deficiency disorders, learning difficulties, and speech/language delays are some of
the more commonly seen clinical features (Bales et al. 2010a; Shprintzen 1978; Shprintzen
1981). Also observed are behavioral, developmental, and psychiatric disorders (reviewed in
Shprintzen 2008).
Developmental delays and cognitive deficits are highly prevalent (80–100%) in children
with 22q11DS, with the mean IQ being 75. In addition, behavioral problems, poor social
skills, language impairments, and speech problems lead to poor academic performance
(Gerdes et al. 2001; Lewandowski et al. 2007; McDonald-McGinn & Zackai 2008; Moss et
al. 1999; Shashi et al. 2011; Sobin et al. 2005; Swillen et al. 1997; Woodin et al. 2001).
Individual assessment and development of educational and therapeutic support programs are
recommended as early as possible to help the child reach his potential (Gerdes et al. 2001).
To date there are no studies pertaining to disclosure of a diagnosis of 22q11DS to the
affected child by the caregivers. We examined the literature on disclosure of other genetic
conditions such as Cystic Fibrosis, carriers of Duchenne Muscular Dystrophy, Familial
Adenomatous Polyposis, carriers of Fragile X syndrome, Hemoglobinopathies, Huntington’s
Disease, Neurofibromatosis, and risk of hereditary cancers to determine if there were themes
of communication that would enable us to frame a study to ascertain factors that determined
disclosure (or not) of a diagnosis of 22q11DS to an affected child by a parent. Although
many of the above conditions affect children, they are dissimilar to 22q11DS since they
involve children whose cognition would be expected to be much higher than children with
22q11DS, as well as children who may not be affected, but are carriers (Forrest et al. 2008;
Gallo et al. 2005; Gallo et al. 2009b; Gaff et al. 2007; McConkie-Rosell et al. 2009;
Metcalfe et al. 2008; Metcalfe et al. 2011; Plumridge et al. 2011; Tercyak et al. 2002).
Nonetheless, the findings in these studies can be summarized as follows: the child/young
adult being informed wanted the person informing them to be knowledgeable (McConkie-
Rosell et al. 2009); parents had differing opinions about the optimal age of the child at
which genetic information could be shared (McConkie-Rosell et al. 2002); the decision to
share was based on parental assessment of the child’s developmental stage, readiness, and
interest (Gallo et al. 2005; Metcalfe et al. 2008); and it was recommended that health care
professionals provide parents information regarding the genetic aspects of their child’s
condition, support so they can feel confident about discussing this with the child, and check
parents’ understanding throughout the child’s development to ensure accuracy of
information (Gallo et al. 2009a).
There are many implications to consider in the disclosure of a genetic diagnosis to a child.
Genetic testing and self-awareness of their diagnosis has the potential to alter parent-child
bonding, incite a change in self-concept, and cause heightened anxiety, especially if the
child is too young or not ready to comprehend the information, and learning that one is
affected or is a carrier can alter the child’s cognitive and psychosocial development (Fanos
1997). However, if information is withheld from an affected child, there is a risk of creating
an environment of secrecy, and a sense of mistrust when the child is informed (Fanos 1997).
Informing the child sooner rather than later allows for time to adjust to the knowledge before
considering how it might affect their own children (McConkie-Rosell et al. 2002), and
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disclosure at a younger age may also allow for the development of more realistic
expectations for the child regarding developmental, behavior, or learning delays (Blomquist
et al. 1998). Despite the above findings, little is known about the effects of growing up with
knowledge of a genetic diagnosis (McConkie-Rosell & Spiridigliozzi 2004).
Furthermore, it is not uncommon for individuals with genetic conditions to also experience
behavioral or psychiatric disorders (reviewed in Dykens 2000), which may present
additional challenges to the disclosure process. Anxiety, difficulties maintaining attention,
perseverative thought patterns, and deficits in social skills are common in children with
22q11DS (Swillen 1997; Swillen 1999; Woodin 2001; Fine 2005; Niklasson 2005).
Approximately 20–40% of adolescents and young adults with 22q11DS will develop a
major psychiatric illness, most commonly schizophrenia but also bipolar disorder, severe
depression, and schizoaffective disorder (Shprintzen 1992; Papolos 1996; Bassett 1998), and
parents report this to be their single greatest source of anxiety (Hercher 2008). Parents may
fear of the impact of disclosure as an additional environmental stressor on the future
development of psychiatric problems.
The diagnosis of any genetic condition in a child can result in families seeking guidance
from genetic counselors and other health care professionals for assistance in how to disclose
the information to the child. Previous research regarding the complex topic of genetic testing
in children has demonstrated that successful genetic counseling requires active partnering
between the family and the professional to achieve a common goal: positive adaptation of
the child to the genetic information (McConkie-Rosell & Spiridigliozzi 2004). Consideration
of how the child may view the information is critical, and the child should be given the
chance to respond and have his or her concerns addressed (McConkie-Rosell &
Spiridigliozzi 2004). Although we derive knowledge about genetic diagnosis disclosure
from other genetic diagnoses where there are published data, as summarized above, there is
a need for empiric data on 22q11DS. Although children with this condition have
neurocognitive impairments, fifty percent have an intellect in the borderline to normal range,
potentially making many of them capable of understanding their genetic diagnosis and its
implications. However, many suffer from numerous psychological and psychiatric problems
as described above, making it more complex for parents to convey the information and to
monitor the consequences of this on their child’s psychological well-being. Thus, reports
investigating communication of information related to other genetic conditions may be
helpful, but do not fit the needs of families with children diagnosed with 22q11DS, making
further research essential.
The current study aimed to gain insight into factors related to the decisions of caregivers in
disclosing a diagnosis of 22q11DS to their child by interviewing caregivers about their
experience. It was hypothesized that the timing and extent of disclosure would be related to
the cognitive functioning and developmental age of the child, as well as the caregiver’s level
of confidence about the information to be shared. Due to the lack of literature available on
how parents decide to disclose their child’s diagnosis of 22q11DS to family and friends, a
secondary objective was to study the factors that influenced how parents shared the
diagnosis with individuals other than the other parent.
Methods
Participants
The participants of this study were primary caregivers of eight children between 10 and 17
years of age diagnosed with 22q11DS who are part of a larger longitudinal study currently in
progress at Duke University Medical Center that examines risk for psychosis in these
children. Background information such as general information about their child’s condition,
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health care treatment, and strategies for progress and development, was obtained.
Demographic data, including current age, age at diagnosis and disclosure, gender and
ethnicity were also obtained.
Instrumentation
An interview guide was developed to examine the caregiver’s experience of informing
others and their child of the 22q11DS diagnosis. This guide was created after reviewing
relevant literature and previously developed guides from related studies (Gallo et al. 2001).
The guide investigated caregiver decisions regarding how and when to inform the child and
others of the diagnosis. A semi-structured interview format was chosen using qualitative
interviews with fairly specific questions that have been previously developed (Berg 2001).
The guide was refined after each interview to adjust for clarity and appropriate content. IQ
information was gathered from the parents’ report as part of the interview, and verified by
the authors.
Procedures
This study was approved by the institutional review board (IRB) at the University of North
Carolina at Greensboro and Duke University Medical Center. Eight families were contacted
by phone and offered participation in a pilot study examining parental disclosure of a
22q11DS diagnosis; all agreed to participate. Interviews were completed either in person or
by phone, recorded, and later transcribed. Transcription of the interviews allowed for coding
of themes and content analysis.
Data Analysis
Demographics were analyzed using frequencies and descriptive statistics. Qualitative data
were analyzed using the Colaizzi method for phenomenology to determine major themes
(Colaizzi 1978). Phenomenology is a method of data analysis that aims to produce a
description of the nature of the reality as seen through an individual’s experience (Priest
2002). It was concluded this was the most appropriate method of data analysis due to the
limited amount of previous research available on this topic, and the limited sample size in
this study.
Categories and themes were formed during analysis of the data obtained through each
interview. The steps of data analysis included reading each transcript multiple times,
extracting significant statements, formulating general meanings, and organizing these
meanings into theoretical clusters (Sanders 2003). Two independent members of the study
team analyzed the transcripts for themes. Quotes representative of each theme were selected
and reported to demonstrate participant experience.
Results
Table I reflects age at which children were diagnosed, age at which they were first informed
of their diagnosis, and age at the time of the interview. In regard to school-related
information, six out of eight participants (75%) stated their child was currently placed in a
mainstream classroom, and seven out of eight (87.5%) stated the use of an individualized
education plan (IEP). The IQ range of the children as reported by the participants, and
verified by the authors through the larger study in which they participate, was from 60–105.
One mother did not recall her child’s IQ. Most children (7/8) were followed regularly by a
geneticist and at least one other subspecialist. Regarding demographics of the interviewees,
all were female, the majority were Non-Hispanic Caucasian (6/8 or 75%), and the majority
had at least some college education (6/8 or 75%).
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Sharing Information about the Diagnosis with Family and Friends
Questions about sharing information related to 22q11DS were separated into two time
frames: when the diagnosis was first made, and the time after this initial period. When asked
who they told at the initial time of diagnosis, all participants reported disclosing the
diagnosis and sharing information about 22q11DS with family members, including
grandparents, aunts and uncles of the child. The children of four participants (50%) were
school-age at the time of diagnosis, while the other four were diagnosed at birth or in
infancy. All of the participants whose children were school-age at diagnosis mentioned
sharing information with the child’s school and teachers at that time. Three participants
(37.5%) said they told close friends about the diagnosis, and one recalled sharing the
information with her church family.
In the time since diagnosis, all participants reported telling teachers at the beginning of each
school year, as well as other individuals who care for the child, such as Scout leaders and
summer camp staff. Additionally, some participants noted informing their supervisor or co-
workers to explain why they may request time to attend medical appointments or other
meetings related to their child, or need to answer a personal cell phone in case of an
emergency. Participants took different perspectives on who to tell, and cited various reasons
for why they decided to tell particular people about the diagnosis (Table II). Themes
reflected participants’ concerns that people may view the child differently when they are
made aware of the diagnosis, as well as their desire for others to learn about 22q11DS to
increase their understanding of the child.
Participants were also asked to rate how emotionally difficult it was to share their child’s
diagnosis with others by placing their feeling on a Likert scale from 1 to 7. Responses are
shown in Table I. The median Likert score was 2, with a mean of 3.143. Participants did not
report a high degree of emotional difficulty. Participants provided comments explaining why
they gave a low or high rating for emotional difficulty of sharing the diagnosis with others
(Table II).
Sharing Information about the Diagnosis with Children
The next set of questions addressed the participant experiences of sharing information with
the affected child. Six out of eight participants (75%) had disclosed the diagnosis of
22q11DS to the child at the time of the interview. When asked what they had told their
children, participants described their experiences as reported in Table II. Of the two who had
not disclosed the diagnosis, one family reported regularly talking with their child about the
medical aspects of the condition, but did not use any technical labels (such as 22q, VCFS, or
DiGeorge syndrome). This participant commented that she feels the child would not
understand those words, but said she sometimes tries to explain in more general terms. At
the time of the interview, the child was 13 years old with an IQ of 64. In the other family
who had not yet informed the child of the diagnosis, the child was 15 years of age with an
IQ of 60. When asked about reasons for deciding not to share the diagnosis information for
now, the participant mentioned significant uncertainty about what to say to the child.
In the six families where the child had been informed, the age of first disclosure ranged from
7 to 12 years, with a mean of 9.6 years. IQs in this group ranged from 71–105. Some
participants said that the child knew all along, but only began to understand the diagnosis
after a certain point when they could start to comprehend the information and its
significance. In half of the families, the participant (mother) was the one to initiate the
discussions, while the other half of participants reported that the child brought up the topic
through questions. All six participants who had disclosed the diagnosis to the child stated
that disclosure occurred over several conversations rather than in one larger discussion.
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Participants reported that conversations occurred most often when children were struggling
with school or on the way to medical appointments.
Motivations and Barriers: Why, When, and What to Say
When asked about their reasons for disclosing the diagnosis to the child, participants
expressed various motivations. These ideas included the need to explain things to the child,
such as why doctor visits were necessary, or why he or she was having a difficult time in
school. Additionally, participants felt it would be important for the child to be aware of his
or her own differences and limitations, wanted their child to develop responsibility, and in
the future, be able to take care of oneself, go to school, or hold a job. Lastly, participants
wanted the child to be aware that the diagnosis was not something to hide or keep secret,
and most noted an open communication style. (Table II)
On the other hand, participants stressed that they didn’t want the child to focus on the
diagnosis or use it as an excuse somehow. Participants also wanted to be certain they could
share the information with the child in a way that would be beneficial, but without “say[ing]
anything that’s going to scare [child], or make [him/her] feel different.” In this way, many
participants expressed uncertainty about words to use when talking with their children about
the diagnosis, both in families that have disclosed the diagnosis and those that have not.
(Table II)
All participants, including those who had not yet disclosed the diagnosis to the child, were
asked to rate how well-equipped they felt to have these types of conversations with their
children, using a Likert scale from 1 to 7, with 1 being not well-equipped at all and 7 being
very well-equipped (Table I). The resulting mean was 4.875, with a mode of 5, indicating
that parents felt reasonably well-prepared to discuss the diagnosis, but may need additional
resources to increase their confidence.
When asked if they had ever received advice about how to tell or talk with the child about
22q11DS, six out of eight participants (75%) responded that they had not. The six
participants who did not receive advice from health care professionals included the four who
had already disclosed the diagnosis to the child and both parents who had yet to disclose.
One participant, who had not yet disclosed the diagnosis to the child, wished she had
received more guidance in this area and expressed her frustration (Table II). Another
participant, who had already disclosed, recalled receiving valuable advice and described
something she found helpful (Table II). When participants were asked about any additional
sources of information they found useful for helping the child understand 22q11DS, no
sources of this type were reported. Most participants said they had talked with their children
using their own strategy, while actively gauging how the child’s understanding had changed
with age (Table II). Lastly, when asked about the age at which they believe a child should be
told about his or her diagnosis of 22q11DS, the majority of participants (7/8 or 87.5%)
mentioned that it depended on when the child could comprehend the information, but this
was not necessarily at a specific age (Table II). Participants expressed that each child may
be ready at a different age, as each child seems to have a different level of understanding,
and that “Sharing information with them has to be just according to the child.”
Discussion
In the current study it was hypothesized that the timing and extent of disclosure of a
22q11DS diagnosis to an affected child by the caregiver would be related to the cognitive
functioning and developmental age of the child, as well as the level of confidence felt by the
caregiver in the information to be shared. The data from this study are consistent with our
hypotheses because participants reported taking into account the child’s ability to understand
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and comprehend the information when making decisions regarding disclosure, and
additionally those who had not yet disclosed the diagnosis felt ill-equipped to have this type
of conversation with the child. Notably, both participants who had not disclosed the
diagnosis to the child had not received any guidance regarding this by health care
professionals. By interviewing caregivers regarding this topic, it was possible to gain insight
into their experiences, and consider how professionals might be able to assist with and
encourage well-equipped, successful disclosure of a 22q11DS diagnosis in the future.
Sharing Information about the Diagnosis with Family and Friends
There is no literature currently available on how parents decide to disclose their child’s
diagnosis of 22q11DS to family and friends. In this study, all participants shared information
with their family members at the time of diagnosis, while close friends, teachers, supervisors
and co-workers were informed later in some cases. Participants whose children were school-
aged at diagnosis reported disclosing to the child’s school and teachers at that time.
Generally there was a low degree of emotional difficulty in disclosing a 22q11DS diagnosis
to these individuals, possibly because they were already aware of the child’s learning, social,
or behavioral difficulties, and informing those in an educational role about the diagnosis
provided an explanation and an avenue for modifying educational strategies. Parents
expressed concern that their child would be viewed differently, but ultimately felt that
sharing information related to the diagnosis would help others to understand their child.
Overall there appeared to be few barriers related to disclosing a diagnosis to family, friends,
and others who care for the child.
Sharing Information about a Diagnosis of 22q11DS with the Affected Child
In the past (with other genetic conditions) it has been found that parents consider when to
share information, what the child needs to know, and how much they feel the child can
handle (Metcalfe et al. 2008). Participants in the current study had similar attitudes and took
these considerations into account: how to talk to their children and what to say when talking
about the diagnosis of 22q11DS. Metcalfe et al. (2008) found the emphasis of open
communication to be a motivating factor for sharing information, and this was also noted by
participants in the current study. However, in our study, about half of families waited for the
child to ask questions before discussing the diagnosis. Some participants stated that they
were always willing to answer the child’s questions, but less comfortable initiating the
discussion. This could reflect a strategy of waiting for the child to indicate readiness to learn
more (McConkie-Rosell et al. 2009).
Parents in our study also reported that disclosure occurred in stages; since many children
with 22q11DS experience difficulties in comprehension, information delivered over several
occasions with repetition could be more efficacious than one discussion, a fact well-known
to the parents based on their day-to-day experiences with their child. The age of the child
was an important factor in disclosure, with the median age being 9.6 years. All the parents in
this study whose children were diagnosed after the newborn or early childhood periods
(n=4) informed their child of the diagnosis at the time it was made. Although we did not
directly ascertain information regarding this, we postulate the following reasons for this high
rate of disclosure. These children were less severely cognitively impaired and therefore
more capable of understanding the diagnosis at that time, borne out by the IQ range in these
children of 75–105. Additionally, the events leading up to the family’s learning about the
diagnosis (i.e. evaluations by medical genetics, blood draw for laboratory testing) during a
time the child was capable of understanding provided an opportunity to initiate the
discussion with the child, whereas parents who learn of the diagnosis at birth are often
managing more urgent medical concerns and may have more difficulty initiating the
discussion as the child develops and matures.
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Although the two individuals with whom the diagnosis had not been shared had the lowest
IQ scores, parents of children with higher IQ scores also reported difficulty sharing the
diagnosis. The mother of a child with an IQ score of 103, an average score for a typically
developing child, reported the highest level of emotional difficulty and felt ill-equipped for
the discussion. The two individuals who did not know their diagnosis yet were also female,
but with a small sample size it is difficult to draw conclusions about this, and thus further
research is needed.
Although our sample size is small, our survey suggests that parental uncertainty of
terminology to use and how to deliver the information were important deterrents to
disclosure of diagnosis to the child. Some participants in our study were hesitant about
talking with the child because they did not want to scare them or were afraid they would not
understand. This reflects a goal of trying to protect the child from potentially painful or
threatening information, often provided in uncertain, indirect, and highly complex
conversations (McConkie-Rosell 2009). Interestingly, none of the parents cited fear of
increasing stress on the child’s mental health state as a barrier to disclosure.
The motivating factors for parents in this study to share information with the child were to
work towards the goals of coping, responsibility, independence, and self-sufficiency. These
are issues of transition for all individuals but are more relevant to children with 22q11DS,
due to the medical and psychological problems with which they grapple. Talking with the
child about his or her diagnosis, and related strengths and challenges, is a major step for
transitioning to independence. Relatedly, providing parents and caregivers with the specific
vocabulary rather than general descriptors will be useful in that process. As explained by
Reiss and Gibson (2002), adolescents require parental support to attain independent health
and social behaviors, and parents, in turn, may require the support of health care providers to
aid in negotiating boundaries, setting goals, and developing these skills. Other factors that
influenced the parent to share the diagnosis included being able to provide the child with an
explanation for their differences and to not hide the diagnosis from their child. Interestingly,
none of the parents mentioned recurrence risks of the deletion as a factor that influenced
disclosure.
Practice Implications
Genetic counselors can help with the process of disclosure by aiding parents in their
discussion of the diagnosis of 22q11DS with the child, through review of genetic concepts,
current issues, and future concerns in a manner sensitive to each family. Health care
professionals can encourage discussion about how to share information, and parents can
allow the child to be involved in clinic visits so that professionals can be involved in
disclosing genetic information (Gallo et al. 2009b). Guidelines for disclosure of a diagnosis
of 22q11DS to the affected child have not been published. Both the participants who had not
disclosed the diagnosis to the child and the 4/6 who had disclosed reported not having
received any guidance from health care professionals. Thus the majority of participants had
received no guidance. This finding has been noted previously with other genetic diagnoses
(Gallo et al. 2005; Metcalfe et al. 2008). While some families may feel that they are
generally knowledgeable and equipped to discuss the diagnosis, advice from health care
professionals may boost their confidence and aid in their success. There are published
resources available which address the unique challenges of genetic counseling for adults
with intellectual disabilities, and many of the suggested approaches may be applied to
children (Finucane 1998, 2010). For example, discussion of probability and risk should be
minimized, using the child’s preferred term for his disability should be considered, and the
use of abstract concepts or analogies should be avoided.
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Based on our preliminary findings, we offer further guidelines for genetic counselors and
points to consider. Since the initiation of the discussion about 22q11DS is difficult for some
parents, providing anticipatory guidance before the child is developmentally ready for the
discussion may give them time to prepare and increase their confidence level. Professionals
can help caregivers learn how to say things in ways that will be most successfully
understood by the child (Metcalfe et al. 2008) and, as suggested by the participants in the
current study, they can also help by sharing their experiences of what has worked well in the
past for other caregivers. They can suggest “the words to use” for parents who are struggling
with finding appropriate language, or offer to role-play this conversation with the parents.
Since the increased risk of psychotic illness is shown to be the greatest source of anxiety for
parents of children with 22q11DS (Hercher 2008), it is possible that this parental anxiety is
an additional barrier to disclosing the diagnosis, but was not detected due to the limited
nature of this study. Genetic counselors may engage parents in a discussion of the possible
positive and negative consequences of disclosure upon their child’s mental health status.
Ongoing and supportive discussion of the diagnosis with the child may increase his
awareness of the possibility of mental health problems, and with this knowledge the child
may report symptoms earlier if they arise. Based on the child’s behavioral history, families
may also be encouraged to pre-arrange supportive therapeutic services in the event that the
discussion incites a negative reaction, such as provoking anxiety or damaging self-image.
Finally, some participants included talking to other families of children with 22q11DS as a
valuable source of guidance regarding what has worked for them; professionals can facilitate
this through support groups and enabling contact with other families with a child with
22q11DS. Thus, genetic counselors have an important opportunity to help families with this
difficult task of diagnosis disclosure.
Study Limitations/Strengths and Future Directions
This pilot study assessed parental disclosure of a 22q11.2 deletion syndrome diagnosis and
was a qualitative study to learn about participants’ experiences. The limitations were that the
study included a small sample size and thus it is difficult to apply conclusions to a larger
population of individuals caring for children with 22q11DS. The interviewees are not
representative of all families of children with 22q11DS. All of the participants interviewed
in this study were mothers, either biological or adoptive, of children diagnosed with
22q11DS; the majority were Non-Hispanic Caucasion; the majority had at least some
college education; and none were diagnosed with 22q11DS themselves (in the wider
population, 1 in 10 affected individuals will have an affected parent). The challenges faced
by an individual with 22q11DS (who likely has cognitive limitations) disclosing the
diagnosis to an affected child are greater than those discussed in this manuscript. These
families will likely need additional support from counselors during the disclosure process. In
addition, questions asked participants to remember specific information and feelings that
may have occurred many years prior to the interview, so there may have been recall bias
associated with the responses. Also participants may have been more likely to respond in
ways they perceived the authors would prefer on particular questions, such as the emotional
difficulty rating.
The strengths are that this is the first examination of diagnosis disclosure to children with
22q11DS, and so provided valuable insight on influencing factors. None of the children with
22q11DS had a major psychiatric illness by the time of these interviews, so the parents’
feelings are not influenced by the effects of psychiatric illness. The interview guide
developed as part of this study may be used as a framework for collecting information for
future studies in this area.
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One of the initial challenges we faced when approaching this study was the lack of an
appropriate conceptual model to guide our exploration of 22q11DS diagnosis disclosure,
since the typical intellect of these children is in the borderline range and many models, such
as the concept of open communication discussed previously, presume typically developing
children. Although Gallo (2001; 2005; 2009a; 2009b; 2010) has significantly contributed to
the literature regarding how families share information with children about genetic
conditions and employs the family management style framework (FMSF) model, this does
not sufficiently address the unique challenges faced by parents of children with 22q11DS.
Parents and caregivers of children with 22q11DS have the need to communicate in a method
suitable to a child with cognitive disabilities. They are also trying to balance the desire to
share information with their child, with the fear of causing more psychological harm. Since
none of the currently existing models appear to fit this population well, these were not tested
in our study.
This current study could be expanded upon by increasing sample size, as well as the use of a
quantitative study design based on these qualitative data. Additional research including the
perspectives of fathers, siblings, or other extended family members would be valuable to the
field. The development of materials to help guide parents in disclosure of a diagnosis to their
child, along with more child-oriented educational materials would be important. Since this
study, the authors have partnered with the local North Carolina 22q11DS support group to
begin development of these materials. The first booklet “Growing up with 22q,” designed to
aid parents in initiating the disclosure discussion, is currently in print (Schoch 2012).
Finally, investigating children’s understanding of 22q11DS, the impact of that information,
and who they choose to share this information with would also be of interest, as well as
studies more specifically addressing how parents or caregivers talk to children about the
psychiatric issues related to 22q11DS.
Conclusion
No prior studies exist regarding disclosure of a 22q11DS diagnosis to the affected child, the
variables that may influence this process, and the support caregivers may require for
successful disclosure. The interview guide developed for this study allowed insights into
participant experiences: parents had little difficulty in sharing the diagnosis with family and
friends, but more challenges in disclosing the diagnosis to the affected child. We were able
to discern parental decision-making factors, as well as concerns and barriers related to
sharing information about 22q11DS with their child. Influential factors included the
developmental level, understanding, and interest of the child. Barriers consisted of not
knowing what words to use or how to initiate the discussion. Results showed that while
parents felt reasonably well equipped to have these discussions with their children, they had
received minimal guidance regarding how to navigate this challenge, indicating that
professionals need to initiate such discussions. Further research is needed to expand upon
the knowledge gained through this study. With each experience that is shared, genetic
counselors and other health care professionals can continue to advance their ability to aid in
the process of successful parental disclosure of a 22q11DS diagnosis.
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Table II
Representative Quotes from Participants
Topic Quote
(1) Sharing information about a
22q11DS diagnosis with family/
friends/others
“At the initial time of diagnosis, it was just to share our sort of shock. And it was a trauma, that’s not too
strong of a word, because we were just reeling from it… And he had this great teacher, so we also wanted
her support. But I struggled with ‘How do I tell?’ and ‘What do I tell?’ because I didn’t want anybody to
look at my child as defective… So I guess we kept it fairly close for a while.”
“It is what it is… it is part of who he is. And it explains some things, sometimes, about him. But then the
other side of that is, I don’t ever want anybody to look at him as defective in any way. Because he’s not.”
“I have concern, I don’t want [child] to be labeled like that, like a child with a syndrome. So I am more
careful. I don’t tell every parent, like all the parents of her friends. Sometimes I still get confused and I
don’t know how much detail I should give them or not.”
“We were pretty much just telling whoever. It was no secret… We were just thrilled to finally have
answers… And there were so many people somehow connected with him, from school to friends to
family, so there were a lot of people we told because so many people had been involved with him already
at that point.”
“For me, you cannot hide it from people… it’s just my opinion. Because people can help you when they
know. And for us, my husband and me, we always tried to be honest with people, that’s what she has,
that’s what she was born with.”
“I guess the two things that I have always wanted people to know is, number one, what [child] has, so that
they’ll know why she’s a little quirky and a little different maybe. And number two, I’ve always wanted to
educate people, since we found out, about what it is.”
(2) Emotional difficulty of
disclosing a diagnosis of
22q11DS to others
Low rating: “I think it wasn’t emotionally hard at that point because we were just so relieved to finally
have some understanding of what in the world was going on. We had been so frustrated for so long, not
being able to figure out what was happening… I think that hardest part for us is really the emotional side
of it coming into play now, more so than when we first found out, because [child] is becoming more
aware of it.”
Low rating: “No [it was not emotionally difficult], not at all. I was emotional more in trying to help her…
more that I felt sorry for my daughter not to be understood before. More guilty… for not being able to
understand her emotional needs before [rather than emotional about telling others].”
High rating: “It was like being knocked over by a big wave. I felt so clueless, like how could I have raised
this child to this age, and not known. And being so afraid of what it meant for his future.”
(3) Sharing information about
22q11DS with the affected child
“Right from the beginning we told him something… When he was little, we just referred to it as his funky
chromosome. And ‘funky’ in our family is just sort of a fun word, no negative connotation, just kind of
quirky, maybe even cool.”
“I just explained it as how God makes us all different, and whereas God gave some people two kidneys,
he gave you one kidney. And that doesn’t mean you’re bad, it just means you’re different. It means that…
some people can do some things, and you can do other things.”
“We need[ed] to go see this doctor and that doctor. [Child] had to go do all these things. And we saw no
reason to hide from him what was going on, so we started talking to him about it at that point… whenever
we had something we thought we could share, in terms of his understanding.”
“We are just a very open family. We talk openly about anything that’s bothering any of us, whether it’s
me, my husband, or our two children. And we just wanted her to know that she could always talk to us.”
“I think the biggest thing is ‘We want to help you. And when you let us help you, we usually are able to
improve things.’ And by help, it’s not just doing things for him, but it’s creating environments that he can
be successful and have opportunities in. Like in the classroom, getting him an environment that’s going to
work. Once we get him there, it’s up to him… So we hold him accountable, but we want him to know we
are there to help him navigate.”
“She has to know how to make some healthy decisions, how to take care of herself. I say sometimes ‘You
know you are getting older, and maybe want to go to college, and you need to learn how to take care of
yourself.’ We just try to remind her what is part of… a healthy lifestyle. That’s why we start talking
sometimes, related to being healthy. You just need to be addressing all the issues.”
(4) Parental concerns and barriers
regarding disclosure of a
22q11DS diagnosis to the child
“You know, we really have not sat down and had a discussion about… ‘This is what you have.’ We just
don’t know exactly what to do about that, and so consequently we haven’t done anything about it.”
“My biggest problem is just knowing what words to use because her understanding is limited. I can’t say
there is something wrong with your genes because she won’t know what a gene is. And I just don’t know
the words to use so it won’t be scary to her, so that she won’t feel weird or different, and that she will kind
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Topic Quote
of understand. So I guess that’s where I struggle the most, is because you have to do it on her level, and
it’s hard to know the right things to say.”
“I don’t want [child] to use it as an excuse for things… She’ll say ‘Well I can’t do that because I have
VCFS.’ That’s kind of how she is, she could use that to get her own way, and I don’t want her to use it
like an excuse. So I just don’t know how to handle that yet, and we’re working on it.”
“I guess my primary concern has been his self-image, that it remains just as it would for any other child. I
don’t want this to define him. But I do want him to have the information he needs to know to make good
decisions for himself. And that’s a difficult balance to strike.”
(5) Receiving advice about how
to talk with children about
22q11DS
“I don’t feel very well-equipped at all. I sort of feel like I could use help with it… I just don’t know what
words to use so that she’ll be able to understand.”
“Just knowing how and when to talk about it, and like should someone else be there, like should a doctor
be there too? And how to approach it. I suppose with every child, it’s so different, the understanding and
everything. So I suppose it depends on the child. But that’s what I really don’t know. I just don’t know
how to approach it.”
“The pediatrician was very helpful with that [how to talk to the child]. He gave me the analogy of a pie
chart. You know, it’s not a big circle that says 22q. It’s slices, you know… he’s this, he’s that. And 22q is
a slice in that chart. And that was really useful. That was a very good visual… for me, and I remember
sharing it with [child] too, because I thought that was something he could understand as well.”




“I continue to do a lot of reading and looking at different things, trying to learn… because it changes as he
gets older… in how things are affecting him. I’m not an expert overall. I just try to be as much of an
expert as I can on the specific areas I need to know about.”
“I’ve really just had to read and put it in child form for her… I wish there was a book for 22q that an 8 or
9 year old could understand. But I haven’t found that book. So I just always read, and anything that needs
to be shared with her, I try to put it in children’s terminology.”
(7) Opinions about when to
disclose a diagnosis of 22q11DS
to the affected child
“When your child is old enough to understand the first little bit about it, then you tell them. That’s my
feeling.”
“I don’t know if I could put a year on it specifically. But more… categorizing… it as an ability to
understand… when they’re recognizing the differences and asking questions, at whatever age that is. It
could be 4, it could be 7… I mean the kids vary so much, you know.”
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